Capstone Therapeutics Corp. (OTCMKTS:CAPS) and its joint venture affiliate, LipimetiX Development, LLC (“JV”), today will hold a conference call and webcast to provide an operating update, discuss the start of AEM-28 Phase 1 clinical studies and report financial results for the fiscal year 2013. Capstone Therapeutics Corp. (OTCMKTS:CAPS) stock performance was 4.00% in last session and finished the day at $0.260. Traded volume was 57,580.00million shares in the last session and the average volume of the stock remained 20.93K shares. The beta of the stock remained 0.41. Capstone Therapeutics Corp. (OTCMKTS:CAPS) insider ownership is 0.79%.

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, today announced that Bassil Dahiyat, Ph.D., Chief Executive Officer, will present at the 21st Annual BioCentury Future Leaders in the Biotech Industry Conference on Friday, March 28, 2014 at 9:30 a.m. EDT at the Millennium Broadway Hotel & Conference Center in New York, NY. Xencor Inc (NASDAQ:XNCR) dropped -6.06 percent to $10.55 Friday on volume of 334,216.00million shares. The intra-day range of the stock was $10.45 to $11.83. Xencor Inc (NASDAQ:XNCR) has a market capitalization of $288.99million.

In an odd turn of events, both Cubist and Durata Therapeutics Inc (NASDAQ:DRTX) will go before Advisory Committees for their respective antibiotics, indicated as potential treatments for gram-positive skin infections, on March 31. Because of the marked increase in serious skin infections stemming from antibiotic resistant bacteria such as Staphylococcus aureus (MRSA), the Centers for Disease Control (CDC) has stated that there is an urgent need to develop new antibiotics to fill this unmet medical need. Durata Therapeutics Inc (NASDAQ:DRTX)’s stock on Mar 28, 2014 reported a decrease of -5.33% to the closing price of $13.50. Its fifty two weeks range is $6.65-$16.99. The total market capitalization recorded $359.64million. The overall volume in the last trading session was 802,246.00million shares. In its share capital, DRTX has 26.62million outstanding shares.

Boulder-based Clovis Oncology Inc (NASDAQ:CLVS) reported Thursday from a conference in Geneva, Switzerland, that its orally delivered drug, CO-1686, is providing benefits to patients suffering from lung cancer and is being well-tolerated as doses are increased. On Friday, shares of Clovis Oncology Inc (NASDAQ:CLVS) dropped -12.44% to close the day at $70.33. Company monthly performance is recorded as -10.27%. Clovis Oncology Inc (NASDAQ:CLVS) quarterly revenue growth is 19.85%.